全文获取类型
收费全文 | 565篇 |
免费 | 28篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 64篇 |
妇产科学 | 4篇 |
基础医学 | 68篇 |
口腔科学 | 11篇 |
临床医学 | 79篇 |
内科学 | 140篇 |
皮肤病学 | 21篇 |
神经病学 | 4篇 |
特种医学 | 139篇 |
外科学 | 14篇 |
综合类 | 9篇 |
预防医学 | 6篇 |
眼科学 | 4篇 |
药学 | 13篇 |
肿瘤学 | 17篇 |
出版年
2022年 | 2篇 |
2021年 | 5篇 |
2019年 | 1篇 |
2018年 | 6篇 |
2017年 | 1篇 |
2016年 | 4篇 |
2015年 | 9篇 |
2014年 | 9篇 |
2013年 | 14篇 |
2012年 | 6篇 |
2011年 | 10篇 |
2010年 | 23篇 |
2009年 | 19篇 |
2008年 | 8篇 |
2007年 | 5篇 |
2006年 | 11篇 |
2005年 | 8篇 |
2004年 | 4篇 |
2003年 | 10篇 |
2002年 | 3篇 |
2001年 | 3篇 |
2000年 | 4篇 |
1999年 | 4篇 |
1998年 | 35篇 |
1997年 | 48篇 |
1996年 | 46篇 |
1995年 | 37篇 |
1994年 | 20篇 |
1993年 | 23篇 |
1992年 | 7篇 |
1991年 | 13篇 |
1990年 | 9篇 |
1989年 | 17篇 |
1988年 | 29篇 |
1987年 | 21篇 |
1986年 | 28篇 |
1985年 | 17篇 |
1984年 | 5篇 |
1983年 | 6篇 |
1982年 | 5篇 |
1981年 | 14篇 |
1980年 | 6篇 |
1979年 | 5篇 |
1978年 | 8篇 |
1977年 | 9篇 |
1976年 | 5篇 |
1975年 | 9篇 |
1974年 | 1篇 |
1968年 | 1篇 |
1967年 | 1篇 |
排序方式: 共有595条查询结果,搜索用时 0 毫秒
591.
Francisco Leyva Paul WX Foley Shajil Chalil Karim Ratib Russell EA Smith Frits Prinzen Angelo Auricchio 《Journal of cardiovascular magnetic resonance》2011,13(1):29
Background
Myocardial scarring at the LV pacing site leads to incomplete resynchronization and a suboptimal symptomatic response to CRT. We sought to determine whether the use of late gadolinium cardiovascular magnetic resonance (LGE-CMR) to guide left ventricular (LV) lead deployment influences the long-term outcome of cardiac resynchronization therapy (CRT).Methods
559 patients with heart failure (age 70.4 ± 10.7 yrs [mean ± SD]) due to ischemic or non-ischemic cardiomyopathy underwent CRT. Implantations were either guided (+CMR) or not guided (-CMR) by LGE-CMR prior to implantation. Fluoroscopy and LGE-CMR were used to localize the LV lead tip and and myocardial scarring retrospectively. Clinical events were assessed in three groups: +CMR and pacing scar (+CMR+S); CMR and not pacing scar (+CMR-S), and; LV pacing not guided by CMR (-CMR).Results
Over a maximum follow-up of 9.1 yrs, +CMR+S had the highest risk of cardiovascular death (HR: 6.34), cardiovascular death or hospitalizations for heart failure (HR: 5.57) and death from any cause or hospitalizations for major adverse cardiovascular events (HR: 4.74) (all P < 0.0001), compared with +CMR-S. An intermediate risk of meeting these endpoints was observed for -CMR, with HRs of 1.51 (P = 0.0726), 1.61 (P = 0.0169) and 1.87 (p = 0.0005), respectively. The +CMR+S group had the highest risk of death from pump failure (HR: 5.40, p < 0.0001) and sudden cardiac death (HR: 4.40, p = 0.0218), in relation to the +CMR-S group.Conclusions
Compared with a conventional implantation approach, the use of LGE-CMR to guide LV lead deployment away from scarred myocardium results in a better clinical outcome after CRT. Pacing scarred myocardium was associated with the worst outcome, in terms of both pump failure and sudden cardiac death. 相似文献592.
593.
Hemofiltration compared to hemodialysis for acute kidney injury: systematic review and meta-analysis
JO Friedrich R Wald SM Bagshaw KE Burns NK Adhikari 《Critical care (London, England)》2012,16(4):R146-16
ABSTRACT: INTRODUCTION: The objective of this systematic review and meta-analysis was to determine the effect of renal replacement therapy (RRT), delivered as hemofiltration vs. hemodialysis, on clinical outcomes in patients with acute kidney injury (AKI). METHODS: MEDLINE, EMBASE, and CENTRAL databases and conference abstracts were searched to June 2012 for parallel-group or crossover randomized and quasi-randomized controlled trials (RCTs) evaluating hemofiltration vs. hemodialysis in patients with AKI. Two authors independently selected studies and abstracted data on study quality and outcomes. Additional information was obtained from trial authors. We pooled data using random-effects models. RESULTS: Of 6657 citations, 19 RCTs (10 parallel-group and 9 crossover) met inclusion criteria. Sixteen trials used continuous RRT. Study quality was variable. The primary analysis included 3 parallel-group trials comparing similar doses of hemofiltration and hemodialysis; sensitivity analyses included trials comparing combined hemofiltration-hemodialysis or dissimilar doses. We found no effect of hemofiltration on mortality (risk ratio [RR] 0.96, 95% confidence interval [CI] 0.73-1.25, p=0.76; 3 trials, n=121 [primary analysis]; RR 1.10, 95%CI 0.88-1.38, p=0.38; 8 trials, n=540 [sensitivity analysis]) or other clinical outcomes (RRT dependence in survivors, vasopressor use, organ dysfunction) compared to hemodialysis. Hemofiltration appeared to shorten time to filter failure (mean difference [MD] -7 hours, 95%CI[-19,+5], p=0.24; 2 trials, n=50 [primary analysis]; MD -5 hours, 95%CI[-10, -1], p=0.01; 3 trials, n=113 [including combined hemofiltration-hemodialysis trials comparing similar doses]; MD -6 hours, 95% CI[-10, -1], p=0.02; 5 trials, n=383 [sensitivity analysis]). Data primarily from crossover RCTs suggested that hemofiltration increased clearance of medium to larger molecules, including inflammatory cytokines, compared to hemodialysis, although almost no studies measured changes in serum concentrations. Meta-analyses were based on very limited data. CONCLUSIONS: Data from small RCTs do not suggest beneficial clinical outcomes from hemofiltration, but confidence intervals were wide. Hemofiltration may increase clearance of medium to larger molecules. Larger trials are required to evaluate effects on clinical outcomes. 相似文献
594.
Ron Wald Jan O Friedrich Sean M Bagshaw Karen EA Burns Amit X Garg Michelle A Hladunewich Andrew A House Stephen Lapinsky David Klein Neesh I Pannu Karen Pope Robert M Richardson Kevin Thorpe Neill KJ Adhikari 《Critical care (London, England)》2012,16(5):R205
Introduction
Among critically ill patients with acute kidney injury (AKI) needing continuous renal replacement therapy (CRRT), the effect of convective (via continuous venovenous hemofiltration [CVVH]) versus diffusive (via continuous venovenous hemodialysis [CVVHD]) solute clearance on clinical outcomes is unclear. Our objective was to evaluate the feasibility of comparing these two modes in a randomized trial.Methods
This was a multicenter open-label parallel-group pilot randomized trial of CVVH versus CVVHD. Using concealed allocation, we randomized critically ill adults with AKI and hemodynamic instability to CVVH or CVVHD, with a prescribed small solute clearance of 35 mL/kg/hour in both arms. The primary outcome was trial feasibility, defined by randomization of >25% of eligible patients, delivery of >75% of the prescribed CRRT dose, and follow-up of >95% of patients to 60 days. A secondary analysis using a mixed-effects model examined the impact of therapy on illness severity, defined by sequential organ failure assessment (SOFA) score, over the first week.Results
We randomized 78 patients (mean age 61.5 years; 39% women; 23% with chronic kidney disease; 82% with sepsis). Baseline SOFA scores (mean 15.9, SD 3.2) were similar between groups. We recruited 55% of eligible patients, delivered >80% of the prescribed dose in each arm, and achieved 100% follow-up. SOFA tended to decline more over the first week in CVVH recipients (-0.8, 95% CI -2.1, +0.5) driven by a reduction in vasopressor requirements. Mortality (54% CVVH; 55% CVVHD) and dialysis dependence in survivors (24% CVVH; 19% CVVHD) at 60 days were similar.Conclusions
Our results suggest that a large trial comparing CVVH to CVVHD would be feasible. There is a trend toward improved vasopressor requirements among CVVH-treated patients over the first week of treatment.Trial Registration
ClinicalTrials.gov: NCT00675818相似文献595.
John M Finney A Sarah Walker Tim EA Peto David H Wyllie 《BMC medical informatics and decision making》2011,11(1):7